# Immix Biopharma, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Immix Biopharma, Inc.). ## Overview Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing CAR-T cell therapies for AL amyloidosis and other serious diseases. Its lead program, NXC-201, is in Phase 1b/2 clinical testing in the U.S. and ex-U.S., with orphan drug designations from both the FDA and European Commission. ## Products & services • NXC-201 CAR-T cell therapy for AL Amyloidosis • NEXICART-2 U.S. Phase 1b/2 clinical trial • NEXICART-1 ex-U.S. Phase 1b/2a clinical trial • Product candidate manufacturing for clinical development • IP, regulatory and clinical development activities - **Lead cell therapy program** (0%) — Development of NXC-201, a CAR-T therapy targeting AL amyloidosis and other serious diseases. - **Clinical trial operations** (0%) — Execution of U.S. and ex-U.S. clinical studies to generate safety and efficacy data. - **Manufacturing and scale-up** (0%) — Manufacturing of product candidates for trials, regulatory readiness, and eventual commercialization. - **Intellectual property and development platform** (0%) — Patent prosecution, licensing, and development of additional product candidates or technologies. - NXC-201 CAR-T cell therapy for AL Amyloidosis - NEXICART-2 U.S. Phase 1b/2 clinical trial - NEXICART-1 ex-U.S. Phase 1b/2a clinical trial - Product candidate manufacturing for clinical development - IP, regulatory and clinical development activities ## Customers Immix Biopharma does not sell commercial products yet; its immediate counterparties are clinical trial sites, investigators, suppliers, and grant/capital providers that fund development. If approved, the eventual customers would be hospitals, treatment centers, and patients with AL amyloidosis or other serious diseases treated through specialty oncology/hematology channels. - **Clinical trial participants** (primary) — Patients with AL amyloidosis enrolled in NEXICART-1 and NEXICART-2 to evaluate safety and efficacy. - **Clinical investigators and trial sites** (primary) — Hospitals and research centers that administer the studies and generate regulatory-grade data. - **Future specialty treatment centers** (secondary) — Hospitals and infusion centers that could use NXC-201 if it receives regulatory approval. - **Grant and capital providers** (primary) — Public and private funding sources that finance R&D, manufacturing, and regulatory work. - Clinical trial sites that enroll and treat patients in NEXICART studies - Patients with relapsed/refractory AL amyloidosis eligible for CAR-T therapy - Hospitals and specialty centers that would adopt an approved therapy - Grant providers and investors that fund development before commercialization - Manufacturing and research partners supporting clinical supply and scale-up ## Geography Immix Biopharma is headquartered in the United States and runs its lead clinical program in both the U.S. and ex-U.S. settings. The company also disclosed an Australian subsidiary for tax purposes and received a CIRM grant tied to U.S.-based clinical development, so its operating footprint is still concentrated around development activities rather than commercial sales. - United States is the core operating base and primary clinical market - NEXICART-2 is a U.S. Phase 1b/2 study - NEXICART-1 is an ex-U.S. Phase 1b/2a study - Australian subsidiary creates some non-U.S. tax exposure - No commercial revenue geography disclosed; business remains development-stage ## Strategy The company’s strategy is to advance NXC-201 through clinical development, secure regulatory support, and build the manufacturing and operational capabilities needed for eventual commercialization. It is also pursuing external funding, including grants and equity financing, to support a capital-intensive development path while expanding its intellectual property and pipeline optionality. - **Clinical advancement of NXC-201** (short-term) — Clinical data is the main value driver for a pre-revenue cell therapy company. - **Regulatory and orphan-drug positioning** (medium-term) — Regulatory designations can improve development efficiency and market access prospects. - **Manufacturing and commercialization readiness** (medium-term) — Cell therapies require specialized supply chain and manufacturing scale before launch. - Advance NXC-201 through Phase 1b/2 clinical development - Use orphan drug designations to support regulatory and market positioning - Fund operations through equity raises and non-dilutive grants - Build manufacturing and commercialization readiness before approval - Expand collaborations and additional product candidate opportunities ## Risks Immix Biopharma is exposed to the typical risks of a clinical-stage biotech: trial failure, regulatory delay, and the need to raise capital before any product revenue exists. Its disclosures also highlight going-concern risk, dependence on external funding, and the high cost of manufacturing, IP protection, and public-company operations. - **Ability to continue as a going concern** [critical] — The company has recurring losses, negative operating cash flow, and depends on external capital and grants. - **Clinical development failure** [high] — NXC-201 is still in early-stage trials, so safety or efficacy issues could halt development. - **Regulatory approval risk** [high] — Approval depends on trial outcomes and regulator review, which can be delayed or denied. - **Capital raising and dilution** [high] — The business is funded primarily through equity offerings and grant reimbursements. - **Manufacturing and scale-up execution** [medium] — Cell therapy production is complex and costly, especially before commercial launch. - Going-concern risk if financing is not available on acceptable terms - Clinical trial failure or delay could impair NXC-201 value - Regulatory setbacks could postpone approval and commercialization - High cash burn from R&D, manufacturing, and public-company costs - IP disputes or patent weakness could reduce exclusivity ## Accounting The most important accounting judgments are tied to R&D expense timing, grant reimbursements, and valuation of intangible and long-lived assets. As a pre-revenue biotech, quarterly results can swing materially with clinical trial timing, manufacturing spend, and any changes in estimates for legal matters, VIEs, or asset impairment. - **Research and development expense timing** — Affects operating loss and comparability across periods - **Grant accounting** — Affects other income and net cash burn - **Intangible asset and long-lived asset valuation** — Potential impairment charges if program value weakens - **Revenue recognition** — Could materially change reported results once commercialization begins - R&D expense timing affects quarterly loss volatility - Grant reimbursements reduce net cash burn and can lag spending - Revenue recognition is limited or absent until commercialization - Intangible and long-lived asset valuation may require impairment testing - Estimates for legal matters and VIEs can change reported liabilities --- *Last updated: 2026-04-28T20:17:00.665258+00:00*